Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paroxetine hydrochloride
Drug ID BADD_D01680
Description Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others.[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters.[A31914] Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.[A31914] The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Indications and Usage Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.[L3358] One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause.[L7703] Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).[A1093,A181754,A181904]
Marketing Status approved; investigational
ATC Code N06AB05
DrugBank ID DB00715
KEGG ID D05374
MeSH ID D017374
PubChem ID 62878
TTD Drug ID D06GDY
NDC Product Code 65862-155; 16714-184; 49999-632; 65841-098; 65862-157; 67544-492; 68084-045; 68084-046; 71335-9650; 60505-0402; 60505-1317; 68084-044; 68788-0797; 0904-5676; 60505-1318; 60505-4520; 69584-673; 60429-735; 60505-4519; 69584-671; 16714-183; 60505-4377; 60505-4379; 68071-4283; 68788-9074; 69584-672; 71335-1205; 65862-154; 43353-845; 43353-994; 60429-736; 65841-099; 65841-601; 65862-156; 61187-005; 16714-182; 60429-737; 60505-0083; 60505-1316; 60505-4517; 60505-4518; 70518-0993; 70518-2871; 55154-7999; 60429-734; 60505-0084; 60505-0097; 62175-470; 62175-471; 67544-317; 62175-472; 63629-8527; 0904-5677; 16714-181; 60505-0101; 60505-4378; 65841-097; 68084-047; 69584-674; 70518-1460; 70518-2118
UNII X2ELS050D8
Synonyms Paroxetine | Aropax | BRL-29060 | BRL 29060 | BRL29060 | FG-7051 | FG 7051 | FG7051 | Paroxetine Acetate | Seroxat | Paroxetine Hydrochloride Anhydrous | Paroxetine Maleate | Paroxetine, cis-(+)-Isomer | Paroxetine, cis-(-)-Isomer | Paroxetine, trans-(+)-Isomer | Paxil | Paroxetine Hydrochloride Hemihydrate | Paroxetine Hydrochloride, Hemihydrate | Paroxetine Hydrochloride
Chemical Information
Molecular Formula C19H21ClFNO3
CAS Registry Number 78246-49-8
SMILES C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary retention20.02.02.011--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.001--
Uterine spasm21.07.03.002--Not Available
Vaginal discharge21.08.02.002--
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vaginal infection11.01.10.002; 21.14.02.002--
Varicose vein24.10.04.001--Not Available
Vascular headache24.03.05.007; 17.14.01.005--Not Available
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasculitis10.02.02.006; 24.12.04.027--
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred06.02.06.007; 17.17.01.010--
Visual field defect06.02.07.003; 17.17.01.001--Not Available
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Withdrawal syndrome08.06.02.012; 19.07.06.023--Not Available
Yawning22.12.03.037--Not Available
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.001--Not Available
Affect lability19.04.01.001--Not Available
Transaminases increased13.03.04.036--Not Available
Faecaloma07.01.03.004--Not Available
Paraesthesia oral17.02.06.008; 07.05.05.035--Not Available
Major depression19.15.01.003--Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages